Open access
Sep 2026
Clinical and Medication-Related Factors Associated with Adverse Renal Outcomes in Advanced Chronic Kidney Disease Patients Treated with Empagliflozin: A Real-World Study in Thailand
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce the rate of chronic kidney disease (CKD) progression and provide cardioprotective benefits beyond glycemic control. However, evidence regarding their effects on kidney disease progression in advanced CKD patients remains limited. Ob...
Ittaprach Yimsuk, Artitaya Vongsaroj, Pikanet Suebchompoo et al.
· Pharmacoepidemiology · 0 citations